The Indian Journal of Sexually Transmitted Diseases and AIDS, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, serves as a vital platform for disseminating research and knowledge in the fields of sexually transmitted infections and HIV/AIDS management. With ISSN 2589-0557 and E-ISSN 2589-0565, this journal aims to bridge the gap in public health and clinical research by providing peer-reviewed articles that cover a range of topics from epidemiology to therapeutic advancements. Despite its status with an impact factor in the lower quartiles across relevant categories, including Q3 in Dermatology, Q4 in Infectious Diseases, and Q4 in Public Health, it holds potential for growth and greater visibility within the academic community. The journal's scope spans critical insights and innovative approaches in managing sexually transmitted diseases, and it is committed to fostering scholarly discourse among its readership consisting of researchers, health professionals, and students alike. As it converges from 2018 to 2024, the Indian Journal of Sexually Transmitted Diseases and AIDS continues to underscore the importance of addressing pressing health issues in India and beyond, while offering an accessible resource for those dedicated to this vital field.

AJAR - African Journal of AIDS Research, an esteemed publication by Taylor & Francis Ltd, stands at the forefront of research in the field of HIV/AIDS, with a specific focus on the African continent. Established in 2003 and publishing continuously through 2024, this journal serves as a crucial platform for disseminating innovative research findings aimed at addressing the challenges of HIV/AIDS. With its ISSN 1608-5906 and E-ISSN 1727-9445, AJAR is indexed in prominent databases and holds a respectable Q3 rating in major categories such as Infectious Diseases, Medicine, Public Health, and Virology as of 2023. This positions the journal as a relevant resource for scholars and medical professionals looking to stay informed on the latest developments and strategies in AIDS research. Although it is not currently an open-access journal, AJAR provides readers with valuable insights that are essential for advancing public health initiatives and infectious disease research across Africa and beyond. The journal's commitment to high-quality peer-reviewed research underscores its importance within its field, making it a vital resource for researchers, students, and policymakers alike.

Turkderm - Turkish Archives of Dermatology and Venerology, published by GALENOS PUBL HOUSE, serves as a vital platform for the dissemination of innovative research and advancements in the fields of dermatology and venerology. With an Open Access policy implemented since 2002, this journal aims to provide free and unrestricted access to significant findings, ensuring that vital information reaches a global audience. Based in Turkey, the journal has positioned itself as an important resource for professionals, researchers, and students alike, despite currently being categorized in Q4 of both Dermatology and Infectious Diseases as per the 2023 metrics. Although it faces competition in the rankings, with a Scopus standing of #131 in Dermatology and #331 in Infectious Diseases, its dedication to advancing knowledge in these critical health areas is unwavering. The journal continually invites original research, reviews, and case studies that enhance clinical practices and foster understanding in the dermatological community.

LEPROSY REVIEW is a distinguished academic journal published by LEPRA in the United Kingdom, dedicated to advancing the understanding of leprosy and related infectious diseases. Since its inception, the journal has been a pivotal platform for disseminating research findings, clinical insights, and reviews in the fields of Dermatology, Infectious Diseases, and broader Medical Science. With an established history spanning from 1945 to the present, it has been categorized in the Q3 quartile for several subjects as per the latest 2023 rankings, indicating its valuable contributions to the scientific community. Although not an Open Access publication, LEPROSY REVIEW offers an important forum for researchers, healthcare professionals, and students to explore the nuances of leprosy research and treatment. Its impact in fostering academic dialogue around neglected tropical diseases is underscored by its rankings in Scopus, making it an essential resource for anyone invested in the fight against leprosy and enhancing the quality of life for affected populations.

HIV Medicine is a prestigious journal published by Wiley that stands at the forefront of research in the fields of health policy, infectious diseases, and pharmacology, with a commendable impact factor reflected in its Q1 rankings for 2023. Established in 1999 and set to converge its expertise through 2024, this journal plays a critical role in advancing the understanding and treatment of HIV and related health challenges. It is esteemed for its rigorous peer-review process and its contributions to both clinical and policy-oriented discussions surrounding HIV medicine. With a broad international readership, it serves as a vital resource for researchers, healthcare professionals, and students committed to fighting the global HIV epidemic. Although not open access, its vital insights are indispensable for anyone involved in infectious disease research and healthcare policy. Articles published in HIV Medicine shape global health strategies and influence the future of HIV research, making it a must-read for those dedicated to this crucial field.

Current HIV/AIDS Reports, published by Springer, is a distinguished scholarly journal that addresses critical developments in the field of HIV/AIDS research. As a leading publication within the Q1 quartiles for both Infectious Diseases and Virology, it serves as an essential platform for researchers and healthcare providers aiming to advance knowledge and practices related to HIV prevention, treatment, and care. With a commitment to publishing innovative studies, reviews, and clinical guidelines, this journal fosters a comprehensive understanding of the complexities surrounding HIV/AIDS. The journal enjoys a robust reputation, evidenced by its impressive Scopus rankings, including a rank of #69 in Infectious Diseases and #21 in Virology, placing it in the top echelons of its field. With an open-access model, *Current HIV/AIDS Reports* significantly enhances the accessibility of crucial research findings to a global audience, driving progress in HIV/AIDS knowledge and public health.

Journal of HIV-AIDS & Social Services is a pivotal academic platform committed to advancing the understanding and management of HIV-AIDS through the lens of social services. Published by Routledge Journals, Taylor & Francis Ltd, this journal spans significant years from 2002 to 2024, making it a key resource for the latest research and practices in the intersecting fields of health and social sciences. With an ISSN of 1538-1501 and an E-ISSN of 1538-151X, the journal holds a respectable position within the academic community, marked by its categorization in the Q3 quartile of both Health (Social Science) and Infectious Diseases as of 2023. The journal strives to provide a forum for innovative research addressing the complexities of HIV-AIDS, incorporating perspectives from various stakeholders, including healthcare providers, policymakers, and community organizations. Although it currently does not offer open access options, its indexed presence and dedicated readership ensure the dissemination of vital knowledge in a field that is more critical than ever. For researchers, professionals, and students dedicated to combating HIV-AIDS, this journal serves not just as a publication, but as a catalyst for change in global health initiatives.

Therapeutic Advances in Infectious Disease is a distinguished journal published by SAGE Publications Ltd, dedicated to advancing knowledge in the vital field of infectious diseases and pharmacology. With an impactful Open Access model since 2019, the journal facilitates unrestricted access to a wealth of high-quality research, enabling researchers, clinicians, and educators to stay at the forefront of infectious disease management and treatment. As a recognition of its contribution to the scientific community, the journal holds a prestigious Q1 quartile ranking in both Infectious Diseases and Medical Pharmacology as of 2023, underscoring its influence and relevance in these domains. The journal is positioned favorably within the Scopus rankings, with an impressive standing in the diverse categories of Medicine, emphasizing its commitment to disseminating innovative research. Through a rigorous peer-review process and a broad scope that covers therapeutic advancements, Therapeutic Advances in Infectious Disease serves as an essential resource for anyone involved in combating infectious diseases, offering insights that drive clinical applications and enhance patient care.

Current HIV Research is a pivotal journal dedicated to the latest advancements in the field of HIV research, published by Bentham Science Publishers Ltd. With a commitment to disseminating high-quality research, this journal serves as a critical resource for researchers, healthcare professionals, and students interested in infectious diseases and virology. The journal has an ISSN of 1570-162X and an E-ISSN of 1873-4251, reflecting its commitment to contemporary digital scholarship. Given its publication history spanning from 2003 to 2024, the journal has continually provided insights and peer-reviewed articles that foster knowledge and innovation in HIV research. Although it currently holds a Q3 ranking in Infectious Diseases and a Q4 ranking in Virology, these rankings underscore its importance as an emerging platform for critical research dialogue. Despite not being an Open Access journal, 'Current HIV Research' ensures that cutting-edge studies reach relevant practitioners and contribute to ongoing discourse in the medical community. By fostering an informed approach to HIV and its implications, this journal is an invaluable asset to those committed to advancing their expertise in this crucial area of health science.

AIDS, published by Lippincott Williams & Wilkins, stands as a premier journal within the fields of immunology and infectious diseases, reflecting a distinguished history since its inception in 1987 and offering insights that shape contemporary research and practice. With an impressive impact factor and categorized in the Q1 quartile across critical areas including Immunology, Infectious Diseases, and Immunology and Allergy, the journal showcases high-quality, peer-reviewed articles that consistently contribute to the advancement of knowledge and innovation in the fight against AIDS and related conditions. Researchers and professionals will find its content invaluable, as it brings forth groundbreaking studies, novel therapeutic approaches, and comprehensive reviews that inform both clinical practices and public health policies. Although not an open access journal, it remains a vital resource for those committed to addressing one of the most pressing global health challenges of our time.